Literature DB >> 22740693

The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.

Shuangping Liu1, Leilei Li, Yingyi Zhang, Yiwen Zhang, Yu Zhao, Xiaona You, Zhenhua Lin, Xiaodong Zhang, Lihong Ye.   

Abstract

We have reported that hepatitis B X-interacting protein (HBXIP) promotes the proliferation and migration of breast cancer cells. However, the underlying mechanism is poorly understood. In this study, we report that HBXIP works in the event through up-regulating S100A4. We observed that HBXIP expression was positively correlated to that of S100A4 in 87 clinical breast cancer tissue samples. Then, we identified that HBXIP was able to up-regulate S100A4 expression in breast cancer cells. Notably, we observed the HBXIP nuclear localization, implying that HBXIP may be associated with the promoter of S100A4. Chromatin immunoprecipitation assay (ChIP) and electrophoretic mobility shift assay (EMSA) showed that HBXIP was able to bind to the nucleotides +200~+239 region of S100A4 promoter, containing two putative recognition motif of transcription factor STAT4 and GRβ. It suggests that HBXIP is able to activate S100A4 promoter via interacting with STAT4 in breast cancer cells, leading to the up-regulation of S100A4. In addition, we identified another pathway of S100A4 up-regulation mediated by HBXIP. We found that HBXIP activated the PTEN/PI3K/AKT signaling by inducing DNA methylation of PTEN, which subsequently boosted S100A4 expression. In function, we demonstrated that HBXIP enhanced the growth or migration of breast cancer cells through S100A4 in vivo and in vitro. Collectively, we conclude that HBXIP up-regulates S100A4 through activating S100A4 promoter involving STAT4 and inducing PTEN/PI3K/AKT signaling to promote growth and migration of breast cancer cells. Our finding provides new insight into the mechanism of HBXIP in promotion of the development of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740693      PMCID: PMC3436276          DOI: 10.1074/jbc.M112.343947

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2.

Authors:  Changliang Shan; Fuqing Xu; Shuai Zhang; Jiacong You; Xiaona You; Liyan Qiu; Jie Zheng; Lihong Ye; Xiaodong Zhang
Journal:  Cell Res       Date:  2010-04-13       Impact factor: 25.617

2.  Sumoylation and nuclear translocation of S100A4 regulate IL-1beta-mediated production of matrix metalloproteinase-13.

Authors:  Keally J Miranda; Richard F Loeser; Raghunatha R Yammani
Journal:  J Biol Chem       Date:  2010-08-04       Impact factor: 5.157

3.  Acquired STAT4 deficiency as a consequence of cancer chemotherapy.

Authors:  Ivan P Lupov; Larry Voiles; Ling Han; Allysia Schwartz; Manuel De La Rosa; Kinnari Oza; David Pelloso; Ravi P Sahu; Jeffrey B Travers; Michael J Robertson; Hua-Chen Chang
Journal:  Blood       Date:  2011-10-13       Impact factor: 22.113

4.  Methylation status of the PTEN gene in adenoid cystic carcinoma cells.

Authors:  Xiaoping Fan; Bin Chen; Junli Xu; Huachang Zhang; Feng Deng; Xuerong Xiang
Journal:  Mol Med Rep       Date:  2010-07-26       Impact factor: 2.952

5.  Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

Authors:  Lionel M L Chow; Raelene Endersby; Xiaoyan Zhu; Sherri Rankin; Chunxu Qu; Junyuan Zhang; Alberto Broniscer; David W Ellison; Suzanne J Baker
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

6.  Promotion of cell proliferation by HBXIP via upregulation of human telomerase reverse transcriptase in human mesenchymal stem cells.

Authors:  Feng-ze Wang; Li Sha; Li-hong Ye; Xiao-dong Zhang
Journal:  Acta Pharmacol Sin       Date:  2008-01       Impact factor: 6.150

Review 7.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

8.  Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer.

Authors:  Teresa Cabezón; Julio E Celis; Inge Skibshøj; Jörg Klingelhöfer; Mariam Grigorian; Pavel Gromov; Fritz Rank; June Helen Myklebust; Gunhild M Maelandsmo; Eugene Lukanidin; Noona Ambartsumian
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

9.  ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.

Authors:  Roberto Hernan; Rami Fasheh; Christopher Calabrese; Adrian J Frank; Kirsteen H Maclean; David Allard; Roger Barraclough; Richard J Gilbertson
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

10.  S100A4 overexpression proves to be independent marker for breast cancer progression.

Authors:  Nawfal I Ismail; Gurjeet Kaur; Hasnah Hashim; Mohammed S Hassan
Journal:  Cancer Cell Int       Date:  2008-09-05       Impact factor: 5.722

View more
  40 in total

1.  Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.

Authors:  L Li; R Fang; B Liu; H Shi; Y Wang; W Zhang; X Zhang; L Ye
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

2.  The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.

Authors:  Xiao-Lei Zhou; Xin Guo; Yu-Pin Song; Chong-Yue Zhu; Wei Zou
Journal:  Acta Pharmacol Sin       Date:  2017-11-30       Impact factor: 6.150

3.  Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.

Authors:  Gang Wang; Jia-Hui Chen; Yong Qiang; Dong-Zhi Wang; Zhong Chen
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Hepatitis B X-interacting protein promotes the formation of the insulin gene-transcribing protein complex Pdx-1/Neurod1 in animal pancreatic β-cells.

Authors:  Hang Li; Zhen Wang; Yinghui Li; Runping Fang; Huawei Wang; Hui Shi; Xiaodong Zhang; Weiying Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

5.  Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.

Authors:  Bo-Wen Liu; Tian-Jiao Wang; Lei-Lei Li; Lu Zhang; Yun-Xia Liu; Jin-Yan Feng; Yue Wu; Fei-Fei Xu; Quan-Sheng Zhang; Ming-Zhu Bao; Wei-Ying Zhang; Li-Hong Ye
Journal:  Acta Pharmacol Sin       Date:  2018-06-20       Impact factor: 6.150

6.  MicroRNA-145 Modulates N6-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N6-Methyladenosine Binding YTH Domain Family 2 Protein.

Authors:  Zhe Yang; Jiong Li; Guoxing Feng; Shan Gao; Yuan Wang; Shuqin Zhang; Yunxia Liu; Lihong Ye; Yueguo Li; Xiaodong Zhang
Journal:  J Biol Chem       Date:  2017-01-19       Impact factor: 5.157

7.  Requisite role for Nck adaptors in cardiovascular development, endothelial-to-mesenchymal transition, and directed cell migration.

Authors:  Derek L Clouthier; Cameron N Harris; Richard A Harris; Claire E Martin; Mira C Puri; Nina Jones
Journal:  Mol Cell Biol       Date:  2015-02-17       Impact factor: 4.272

8.  Upregulating the Expression of Survivin-HBXIP Complex Contributes to the Protective Role of IMM-H004 in Transient Global Cerebral Ischemia/Reperfusion.

Authors:  Shi-Feng Chu; Zhao Zhang; Wei Zhang; Mei-Jin Zhang; Yan Gao; Ning Han; Wei Zuo; Hui-Yong Huang; Nai-Hong Chen
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

9.  The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.

Authors:  Hang Li; Qian Liu; Zhen Wang; Runping Fang; Yu Shen; Xiaoli Cai; Yuen Gao; Yinghui Li; Xiaodong Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2015-07-30       Impact factor: 5.157

10.  HBXIP expression predicts patient prognosis in breast cancer.

Authors:  Daye Cheng; Bin Liang; Yunhui Li
Journal:  Med Oncol       Date:  2014-09-02       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.